Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2419Neoplasms 1838Carcinoma, Non-Small-Cell Lung 1591Prostatic Neoplasms 1296Colorectal Neoplasms 1117Lung Neoplasms 981Neoplasm Metastasis 828Multiple Myeloma 793Leukemia, Myeloid, Acute 773Ovarian Neoplasms 673Pancreatic Neoplasms 667Melanoma 660Squamous Cell Carcinoma of Head and Neck 589Recurrence 563Carcinoma, Hepatocellular 562Brain Neoplasms 515Glioblastoma 505Stomach Neoplasms 501Head and Neck Neoplasms 492Triple Negative Breast Neoplasms 471Lymphoma 460Uterine Cervical Neoplasms 444Carcinoma, Renal Cell 426Precursor Cell Lymphoblastic Leukemia-Lymphoma 420Lymphoma, Non-Hodgkin 387Endometrial Neoplasms 377Sarcoma 365Lymphoma, Follicular 357Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 355

Interventions

Yttrium-90 1Radiosurgery 1Positron Emission Tomography Computed Tomography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Liver Malignancy × 1 year × Clear all
NCT04518748 2025-08-05

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

University of Michigan Rogel Cancer Center

Phase 1 Recruiting
70 enrolled

Liver Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡